Colorectal Cancer Incidence Increasing in Younger Adults
Colorectal cancer incidence is increasing among young adults in certain high-income countries.
Gastrointestinal Cancers News
GASTROINTESTINAL CANCER ADVISOR
Gastrointestinal Cancers News
Cyramza Approved to Treat Hepatocellular Carcinoma
The FDA has approved Cyramza (ramucirumab; Lilly) for use as a single agent in the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400ng/mL and have been treated with sorafenib.
Postsurgical ctDNA Levels May Predict Disease Recurrence in Colorectal Cancer
None of the 45 patients who had a negative postoperative ctDNA value experienced a relapse after a median follow-up of 49 months.
Triplet Combination for Biliary Tract Cancers Clears Phase 2 Trial
The addition of nab-paclitaxel to gemcitabine-cisplatin appeared to confer clinical benefit in patients with advanced biliary tract cancers.
Oral Aspirin Does Not Up FIT Test Sensitivity for ID’ing CRC
Administration of a single dose of oral aspirin prior to fecal immunochemical testing does not increase test sensitivity for detecting advanced colorectal neoplasms.
MRI Selects “Good Prognosis” Rectal Cancer Patients for Primary Surgery
Rectal cancer patients with good tumor prognosis according to magnetic resonance imaging criteria may not need preoperative chemoradiotherapy.
No OS Benefit of Immunotherapy Plus MEK Inhibitor for Patients With Microsatellite-Stable Metastatic Colorectal Cancer
RAS tumor status was not predictive of benefit from the combination of atezolizumab and cobimetinib compared with regorafenib.
Cardiorespiratory Fitness Tied to Lower Risk for Lung Cancer, CRC
Higher cardiorespiratory fitness (CRF) is associated with a lower risk for incident lung and colorectal cancer and with a lower risk for all-cause mortality among those diagnosed with lung and colorectal cancer.
AGA Clinical Practice Update: DAAs for Hepatitis C and Hepatocellular Cancer
The AGA present an updated summary of best practice advice for surveillance of hepatocellular cancer and DAA therapy timing.
AFP SPEAR T Cells Deemed Safe in First 2 Treated Patients With Hepatocellular Carcinoma
This first-in-human trial will enroll up to 24 patients.
Less Postoperative Chemotherapy for Pediatric Hepatoblastoma Has No Effect on Disease Control
Fewer chemotherapy cycles could decrease long-term morbidity for certain patients.
Docetaxel Plus S-1 Postoperative Chemotherapy in Stage III Gastric Cancer Found to Improve RFS
Based on an interim analysis showing efficacy for postoperative docetaxel plus S-1 compared with S-1 alone, this trial in stage III gastric cancer was closed early.
Rates of HCV-Related Liver Cancer Deaths Increasing Faster in Individuals With Fewer Years of Education
There were more than 30,000 deaths due to liver cancer in the US during 2018.
CEA Level as an Independent Predictor of Clinical Outcome in Colon Cancer
NCCN guidelines currently say that an elevated serum CEA level is not a high-risk factor that would preclude the use of adjuvant chemotherapy for early-stage colorectal cancer.
Evidence for Benefit of Adjuvant Radiation Therapy in Colon Cancer
Very few patients with resectable, locally advanced colon cancer included in the NCI-SEER database received adjuvant radiation therapy.
Peritoneal Lesion Assignment in the Setting of Gastrointestinal Cancer
Decisions regarding whether to biopsy a peritoneal lesion in gastrointestinal cancer are often based on the physical appearance of the lesion.
Limited Clinical Benefit for the Combination of TRC102 and Temozolomide in Refractory Colorectal Cancer
The median number of prior treatments for patients with relapsed colorectal cancer enrolled in this phase 2 study was 6.
Tumor Biopsy Found Less Effective Than Liquid Biopsy for Identifying Resistance Mechanisms in Some GI Cancers
In 78% of patients, circulating cell-free tumor DNA identified a possible mechanism of acquired resistance not identified by standard tumor DNA sequencing.
COLOMATE: Using a Liquid Biopsy in CRC to Select a Molecularly Targeted Therapy
The companion study arms under the COLOMATE trial umbrella will include those that specifically enroll patients with HER2-amplified or EGFR-mutant disease.
FFPE Tissue Specimens Deemed Adequate for Molecular Studies: NCI-SEER
Regions of tumor and normal tissue on FFPE tissue specimens obtained from the NCI SEER-linked Virtual Tissue Repository were annotated by a pathologist.
Want to read more?
Please login or register first to view this content.
Next post in Gastrointestinal Cancers News
